ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a
combination of ADXS31-142 with Pembrolizumab (MK-3475) in patients with metastatic
castration-resistant prostate cancer. Part A will be dose-determining of ADXS31-142
monotherapy. Part B will be dose-determining of ADXS31-142 and Pembrolizumad (MK-3475) in
combination. Part B expansion will treat additional patients with the recommended dose from
Part B.